You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《美股業績》蛋白新冠疫苗商Novavax(NVAX.US)大削收入預測 市後挫34%
阿思達克 08-09 11:43
新冠疫苗生產商,美國疫苗開發企業Novavax(NVAX.US)公布第二季業績。季度虧損5.1億美元,按年擴大44.9%。每股季度基本虧損6.53美元。季度收入1.86億,按年跌37.6%。 公司預期全年收入介乎20億至23億美元,遠低於原來預測的40億至50億美元。公司承認其蛋白新冠疫苗太晚推出市場,因美國疫苗接種已由mRNA技術的疫苗推動。公司的新冠疫苗至今在美國僅被使用7,381劑次。 Novavax股價在延長交易時段挫33.6%,報37.99美元。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account